Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | HTR2C | P28335 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8870566 | 0.86 | PDE3B (0.41) | CXCR4CXCL12HTR1AHTR2CLMNA | |
| SCHEMBL8870673 | 0.80 | HTR1A (0.42) | HTR1AHTR2CLMNAPDE3BPDE3A | |
| SCHEMBL6190219 | 0.78 | GRIN2B (0.42) | HTR1AHTR2CSMN1; SMN2 | |
| SCHEMBL6190223 | 0.78 | GRIN2B (0.42) | HTR1AHTR2CSMN1; SMN2 | |
| SCHEMBL8948091 | 0.75 | SIGMAR1 (0.54) | HTR1AHTR2C | |
| SCHEMBL6190040 | 0.75 | SPHK1 (0.42) | HTR1AHTR2CSMN1; SMN2 | |
| SCHEMBL7759828 | 0.75 | HTR1A (0.42) | HTR1AHTR2CLMNAPDE3BPDE3A | |
| SCHEMBL9263068 | 0.75 | CXCR4 (0.66) | CXCR4CXCL12LMNASMN1; SMN2 | |
| SCHEMBL9437757 | 0.74 | HTR1A (0.48) | HTR1AHTR2CPDE3BPDE3A | |
| SCHEMBL7756745 | 0.73 | HTR1A (0.63) | HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246159-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS INC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-0673934-B1 | Aminoalkyl benzothiazolinones, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-04-25 | — | — | EP | disclosed |
| CN-1050601-C | Preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 2000-03-22 | — | — | CN | disclosed |
| US-5512569-A | SIGMA RECEPTOR DISORDERS; PSYCHOLOGICAL DISORDERS | ADIR ET COMPAGNIE (FR) | 1996-04-30 | — | — | US | disclosed |
| CN-1111626-A | Preparation and the pharmaceutical compositions which contain them | ADIR (FR) | 1995-11-15 | — | — | CN | disclosed |
| EP-0673934-A1 | Aminoalkyl benzothiazolinones, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246159-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | CXCR4 827/4885CXCL12 788/4885HTR1A 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.